Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
The bill creates a permanent class-wide Schedule I listing for “fentanyl-related substances” using a chemical-structure definition, requires the Attorney General to publish identified substances, and exempts those classed substances from quantity-based mandatory minimum penalties. It amends domestic and import/export penalty statutes to set specific fentanyl and analogue thresholds while excluding classed fentanyl-related substances from quantity-based mandatory minimums.
Progressives favor removal of quantity-based mandatory minimums; conservatives oppose.
Relative to its intended legislative type, this bill is a detailed substantive amendment to the Controlled Substances Act that is precise in statutory drafting, specifies responsible actors and timelines, and anticipates many boundary conditions and procedural interactions, but it does not address costs or resource needs associated with implementing the new responsibilities.
The bill creates a permanent class-wide Schedule I listing for “fentanyl-related substances” using a chemical-structure definition, requires the Attorney General to publish identified substances, and exempts those classed substances from quantity-based mandatory minimum penalties.
It amends domestic and import/export penalty statutes to set specific fentanyl and analogue thresholds while excluding classed fentanyl-related substances from quantity-based mandatory minimums.
The bill gives the Secretary of Health and Human Services (HHS) an expedited, binding process to petition the Attorney General to remove or reschedule such substances, provides retroactive sentencing relief if substances are later removed or rescheduled, streamlines and clarifies research registration and conduct for schedule I research, and requires a GAO report within four years assessing impacts.
Technically significant and partially bipartisan but touches contested sentencing and broad scheduling; Senate hurdles and stakeholder concerns lower odds.
Relative to its intended legislative type, this bill is a detailed substantive amendment to the Controlled Substances Act that is precise in statutory drafting, specifies responsible actors and timelines, and anticipates many boundary conditions and procedural interactions, but it does not address costs or resource needs associated with implementing the new responsibilities.
Progressives favor removal of quantity-based mandatory minimums; conservatives oppose.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives favor removal of quantity-based mandatory minimums; conservatives oppose.
Generally supportive.
The bill pairs aggressive control of novel fentanyl analogues with safeguards: HHS-led scientific review, removal/rescheduling paths, elimination of quantity-based mandatory minimums for classed substances, and research facilitation.
It also creates retroactive relief opportunities for people convicted under later-deemed-lower-risk substances.
Cautiously favorable but pragmatic.
The bill addresses the proliferation of novel fentanyl analogues while creating a science-driven rescheduling mechanism and research streamlining.
Concerns focus on legal clarity, procedural timelines, and balancing law enforcement effectiveness with proportional sentencing.
Generally opposed.
While intending to combat fentanyl, the bill expands federal scheduling broadly, removes quantity-based mandatory minimum sentences for many classed analogues, and shifts decision power to HHS, reducing prosecutorial discretion and penalties.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically significant and partially bipartisan but touches contested sentencing and broad scheduling; Senate hurdles and stakeholder concerns lower odds.
The bill has not accumulated any surfaced votes yet.
Progressives favor removal of quantity-based mandatory minimums; conservatives oppose.
Technically significant and partially bipartisan but touches contested sentencing and broad scheduling; Senate hurdles and stakeholder conc…
Relative to its intended legislative type, this bill is a detailed substantive amendment to the Controlled Substances Act that is precise in statutory drafting, specifies responsible actors and timelines, and anticipate…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.